Xencor Reports Q4 Earnings

Biotech firm beats Wall Street expectations on revenue and loss per share

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

Xencor Inc., a biotech company developing antibodies for severe autoimmune/allergic diseases and cancer, reported a loss of $6.7 million in its fourth quarter. However, the results beat Wall Street expectations, with revenue of $28.2 million exceeding analyst forecasts.

Why it matters

Xencor's financial performance is closely watched by investors and analysts as an indicator of the company's progress in developing its pipeline of antibody therapies. Strong quarterly results can signal momentum in the company's research and development efforts.

The details

For the full year, Xencor reported a loss of $91.9 million, or $1.24 per share, on revenue of $125.6 million. The company's fourth-quarter revenue of $28.2 million beat the average estimate of $21.6 million from six analysts surveyed by Zacks Investment Research.

  • Xencor reported its fourth-quarter results on Wednesday, February 25, 2026.

The players

Xencor Inc.

A biotech company developing antibodies for severe autoimmune/allergic diseases and cancer.

Got photos? Submit your photos here. ›

The takeaway

Xencor's strong financial performance in the fourth quarter, with revenue and loss per share beating analyst expectations, suggests the company is making progress in its efforts to develop innovative antibody therapies for serious medical conditions.